Service of Neurology and Pathology, Hospital Juan Ramón Jiménez, Huelva, Spain.
Neuro Oncol. 2012 Apr;14(4):506-10. doi: 10.1093/neuonc/nos006. Epub 2012 Feb 20.
Isolated case reports suggest that breast tumors from patients with paraneoplastic cerebellar degeneration (PCD) and Yo antibodies overexpress human epidermal growth factor receptor 2 (HER2). HER2 overexpression is present in 15%-25% of breast cancers and is associated with poor prognosis. We retrospectively analyzed the status of HER2 in breast tumors of 27 patients with anti-Yo-associated PCD to evaluate whether HER2 overexpression in this group of patients is higher than expected. In addition, we analyzed HER2 status of 19 breast tumors from patients with paraneoplastic neurological syndromes and Ri antibodies to see whether HER2 was specifically related to anti-Yo-associated PCD. We also assessed cdr2 expression (the onconeural antigen recognized by Yo antibodies) in 21 HER2-positive breast tumors from patients without paraneoplastic neurological syndromes. HER2 was overexpressed in 26 patients (96.3%) with anti-Yo-associated PCD but only in 2 patients (10.5%) with paraneoplastic neurological syndromes associated with Ri antibodies (P< .0001). Only 5 (23.8%) of the 21 HER2-positive breast tumors showed cdr2 immunoreactivity. This study shows a very high frequency of HER2 overexpression in breast cancers in patients with anti-Yo-associated PCD but not in those from patients with Ri antibodies. Although the expression of cdr2 onconeural antigen is not high in HER2-positive breast cancers, HER2 overexpression seems to be an important requirement to develop an anti-Yo-associated PCD.
个案报告提示，副肿瘤性小脑变性（PCD）伴 Yo 抗体的乳腺癌肿瘤过度表达人表皮生长因子受体 2（HER2）。HER2 过表达存在于 15%-25%的乳腺癌中，并与预后不良相关。我们回顾性分析了 27 例抗 Yo 相关 PCD 患者的乳腺癌中 HER2 的状态，以评估该组患者中 HER2 过表达是否高于预期。此外，我们还分析了 19 例伴副肿瘤性神经综合征和 Ri 抗体的乳腺癌中 HER2 的状态，以观察 HER2 是否与抗 Yo 相关 PCD 特异性相关。我们还评估了 21 例无副肿瘤性神经综合征的 HER2 阳性乳腺癌中 cdr2 表达（Yo 抗体识别的神经原性抗原）。抗 Yo 相关 PCD 的 26 例患者（96.3%）HER2 过表达，但仅 2 例（10.5%）伴 Ri 抗体的副肿瘤性神经综合征患者 HER2 过表达（P<.0001）。在 21 例 HER2 阳性乳腺癌中，仅 5 例（23.8%）显示 cdr2 免疫反应性。本研究表明，抗 Yo 相关 PCD 患者的乳腺癌中 HER2 过表达频率非常高，但在伴 Ri 抗体的患者中则不然。尽管 HER2 阳性乳腺癌中 cdr2 神经原性抗原的表达不高，但 HER2 过表达似乎是发生抗 Yo 相关 PCD 的重要条件。
